These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 25739373)

  • 21. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
    Klin Monbl Augenheilkd; 2007 Jul; 224(7):559-66. PubMed ID: 17657689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is There Any Difference between Ranibizumab and Aflibercept Injections in Terms of Inflammation Measured with Anterior Chamber Flare Levels in Age-Related Macular Degeneration Patients: A Comparative Study.
    Demirel S; Bilici S; Batıoğlu F; Özmert E
    Ophthalmic Res; 2016; 56(1):35-40. PubMed ID: 27027523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
    Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
    Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration.
    Finger RP; Xie J; Fotis K; Parikh S; Cummins R; Mitchell P; Guymer RH
    Clin Exp Ophthalmol; 2017 Mar; 45(2):143-151. PubMed ID: 27449314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.
    Roald AB; Aass HC; Moe MC
    Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.
    Singh N; Chang JS; Rachitskaya AV
    Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice?
    Han DP
    JAMA Ophthalmol; 2013 Sep; 131(9):1124-6. PubMed ID: 23744293
    [No Abstract]   [Full Text] [Related]  

  • 29. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.
    Ricci F; Parravano M; Regine F; Sciamanna M; Tedeschi M; Missiroli F; Varano M
    Eye (Lond); 2016 Aug; 30(8):1077-83. PubMed ID: 27229701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness.
    Vottonen P
    Acta Ophthalmol; 2018 Feb; 96 Suppl A109():1-46. PubMed ID: 29468838
    [No Abstract]   [Full Text] [Related]  

  • 31. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
    Beato J; Pedrosa AC; Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Melo A; Estrela-Silva S; Falcão-Reis F; Carneiro ÂM
    Ophthalmic Res; 2016; 56(1):30-4. PubMed ID: 27046391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-VEGF therapy of neovascular age-related macular degeneration: therapeutic strategies status December 2012].
    Pauleikhoff D; Bertram B; Holz FG; Kirchhof B; Bartz-Schmidt U; Bornfeld N; Bresgen M; Eter N; Friedrichs W; Heimann H; Helbig H; Hörauf H; Kampik A; Lemmen KD; Roider J; Ziemssen F
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):170-7. PubMed ID: 23430681
    [No Abstract]   [Full Text] [Related]  

  • 34. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neovascular age-related macular degeneration.
    Veritti D; Sarao V; Lanzetta P
    Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].
    Cervera RE; Castro V; Montero J; Torralba C; Gracia A
    Arch Soc Esp Oftalmol; 2014 Jan; 89(1):42-3. PubMed ID: 24269436
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
    de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
    Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New options in the therapy for neovascular age-related macular degeneration: critieria for repeat treatment in anti-VEGF therapy - current supplementary statement of the Retinological Society, The German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany].
    redaktionellen Mitarbeiter sind am Ende des Beitrags gelistet
    Klin Monbl Augenheilkd; 2011 Feb; 228(2):138-43. PubMed ID: 21328174
    [No Abstract]   [Full Text] [Related]  

  • 40. Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration.
    Wickremasinghe S; Abedi F; Sandhu SS; Guymer R
    Clin Exp Ophthalmol; 2013 Nov; 41(8):723-6. PubMed ID: 24152187
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.